Healthcare provider profile · identity verified

David Bencomo, MD

Allopathic & Osteopathic Physicians|Internal Medicine · PEMBROKE PINES, FL · NPI 1922297191

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show David Bencomo, MD received $78.22 in general payments during 2025 across 3 reported records.

GlaxoSmithKline, LLC. accounted for 34.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$78.22

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$26.87	34.4%	1	2025
Exact Sciences Corporation	Unresolved — no canonical attribution shown	$26.37	33.7%	1	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$24.98	31.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$78.22	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
NUCALA Normalized: nucala	Biological	GlaxoSmithKline, LLC.	$26.87	1	2025
Source payment records 2025-05-15 · GlaxoSmithKline, LLC. · $26.87 · Open Payments source
The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit	Device	Exact Sciences Corporation	$26.37	1	2025
Source payment records 2025-05-16 · Exact Sciences Corporation · $26.37 · Open Payments source
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$24.98	1	2025
Source payment records 2025-08-05 · Lilly USA, LLC · $24.98 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
MOUNJARO mounjaro	2025	Mounjaro	2024	39 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	20	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	133	30
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	39	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	608	196
Atorvastatin Calcium	Atorvastatin Calcium	601	193
Levothyroxine Sodium	Levothyroxine Sodium	423	114
Losartan Potassium	Losartan Potassium	368	127
Rosuvastatin Calcium	Rosuvastatin Calcium	338	123
Gabapentin	Gabapentin	331	121
Pantoprazole Sodium	Pantoprazole Sodium	284	99
Metformin Hcl	Metformin Hcl	263	86
Lisinopril	Lisinopril	247	79
Alprazolam	Alprazolam	220	43
Metoprolol Succinate	Metoprolol Succinate	192	61
Omeprazole	Omeprazole	191	70
Tamsulosin Hcl	Tamsulosin Hcl	182	61
Hydrochlorothiazide	Hydrochlorothiazide	169	56
Simvastatin	Simvastatin	158	53
Pravastatin Sodium	Pravastatin Sodium	157	57
Meloxicam	Meloxicam	148	61
Ozempic	Semaglutide	145	25
Alendronate Sodium	Alendronate Sodium	140	49
Methylprednisolone	Methylprednisolone	139	118
Fluticasone Propionate	Fluticasone Propionate	137	74
Jardiance	Empagliflozin	133	30
Eliquis	Apixaban	120	38
Famotidine	Famotidine	117	42
Trazodone Hcl	Trazodone Hcl	114	37
Albuterol Sulfate Hfa	Albuterol Sulfate	109	48
Donepezil Hcl	Donepezil Hcl	108	29
Tramadol Hcl	Tramadol Hcl	103	38
Metoprolol Tartrate	Metoprolol Tartrate	97	36
Temazepam	Temazepam	96	15
Azithromycin	Azithromycin	94	74
Baclofen	Baclofen	94	52
Diclofenac Sodium	Diclofenac Sodium	94	42
Ezetimibe	Ezetimibe	93	32
Furosemide	Furosemide	88	34
Zolpidem Tartrate	Zolpidem Tartrate	86	12
Potassium Chloride	Potassium Chloride	84	27
Clopidogrel	Clopidogrel Bisulfate	82	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	82	28
Nifedipine Er	Nifedipine	81	29
Carvedilol	Carvedilol	76	25
Linzess	Linaclotide	76	30
Vascepa	Icosapent Ethyl	76	19
Sertraline Hcl	Sertraline Hcl	75	20
Lorazepam	Lorazepam	74	18
Glipizide	Glipizide	72	27
Montelukast Sodium	Montelukast Sodium	72	27
Memantine Hcl	Memantine Hcl	67	22
Sildenafil Citrate	Sildenafil Citrate	64	16
Duloxetine Hcl	Duloxetine Hcl	63	24
Chlorthalidone	Chlorthalidone	62	20
Myrbetriq	Mirabegron	61	22
Clonazepam	Clonazepam	55	suppressed
Allopurinol	Allopurinol	52	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	48	15
Finasteride	Finasteride	47	16
Glipizide Er	Glipizide	47	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	15
Metformin Hcl Er	Metformin Hcl	47	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	47	39
Escitalopram Oxalate	Escitalopram Oxalate	46	20
Meclizine Hcl	Meclizine Hcl	45	18
Mupirocin	Mupirocin	45	37
Oxybutynin Chloride	Oxybutynin Chloride	45	19
Benazepril Hcl	Benazepril Hcl	40	11
Ibuprofen	Ibuprofen	40	13
Glimepiride	Glimepiride	39	12
Mounjaro	Tirzepatide	39	suppressed
Atenolol	Atenolol	38	13
Hydralazine Hcl	Hydralazine Hcl	37	13
Doxycycline Monohydrate	Doxycycline Monohydrate	36	32
Lovastatin	Lovastatin	36	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	34	30
Buspirone Hcl	Buspirone Hcl	34	suppressed
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Warfarin Sodium	Warfarin Sodium	33	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	32	22
Methenamine Hippurate	Methenamine Hippurate	32	15
Prednisone	Prednisone	32	12
Tradjenta	Linagliptin	32	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	31	20
Januvia	Sitagliptin Phosphate	31	suppressed
Enalapril Maleate	Enalapril Maleate	30	suppressed
Irbesartan	Irbesartan	30	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	30	suppressed
Mirtazapine	Mirtazapine	30	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	28	suppressed
Farxiga	Dapagliflozin Propanediol	28	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	28	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	27	11
Ketoconazole	Ketoconazole	27	11
Ondansetron Hcl	Ondansetron Hcl	27	11
Azelastine Hcl	Azelastine Hcl	26	16
Spironolactone	Spironolactone	26	suppressed
Symbicort	Budesonide/Formoterol Fumarate	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	20
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	24	11
Latanoprost	Latanoprost	24	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	23	suppressed
Amoxicillin	Amoxicillin	21	20
Bupropion Hcl	Bupropion Hcl	21	suppressed
Trulicity	Dulaglutide	21	suppressed
Cefuroxime	Cefuroxime Axetil	20	17
Celecoxib	Celecoxib	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Levetiracetam	Levetiracetam	20	suppressed
Metronidazole	Metronidazole	20	17
Ondansetron Odt	Ondansetron	20	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	20	suppressed
Valsartan	Valsartan	20	suppressed
Hydrocortisone	Hydrocortisone	19	14
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	17
Synthroid	Levothyroxine Sodium	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Labetalol Hcl	Labetalol Hcl	18	suppressed
Ramipril	Ramipril	18	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	17	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	17	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	17	17
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Lidocaine	Lidocaine	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	15	suppressed
Calcitriol	Calcitriol	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	15
Jantoven	Warfarin Sodium	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Digoxin	Digoxin	14	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Clotrimazole	Clotrimazole	13	suppressed
Dutasteride	Dutasteride	13	suppressed
Nystatin	Nystatin	13	suppressed
Raloxifene Hcl	Raloxifene Hcl	13	suppressed
Lumigan	Bimatoprost	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Naproxen	Naproxen	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Somatuline Depot	Lanreotide Acetate	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Ampicillin Trihydrate	Ampicillin Trihydrate	11	suppressed
Combigan	Brimonidine Tartrate/Timolol	11	suppressed
Memantine Hcl Er	Memantine Hcl	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$78.22 · 3 records	GlaxoSmithKline, LLC.	MOUNJARO, NUCALA, The Cologuard Plus Collection Kit	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Mounjaro play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error